Alendronate to Prevent Loss of Bronchoprotection in Asthma

Inclusion Criteria: * Clinical history consistent with moderate asthma for \>1 year * Asthma is controlled with ICS, with an FP dose ≤ 1000mcg/day and \>100mcg/day (or equivalent) * Able to perform reproducible spirometry according to ATS criteria * Baseline FEV1 ≥ 50% of predicted and ≥1L. * If FEV1 \<80%, a minimum 12% increase in FEV1 post-bronchodilator or a MCh PC20 ≤ 8 mg/mL * If FEV1 ≥80%, a MCh PC20 ≤ 8 mg/mL * Salmeterol protected MCh ≤ 16 mg/mL Exclusion Criteria: * Uncontrolled asthma, as suggested by an ACT score \<18 while on high-dose ICS (FP daily dose \>500mcg or equivalent) * Non-ICS controller medication or LABA use within 4 weeks of study entry. * Contraindications to use of bisphosphonates: history of intolerance to bisphosphonates, history of esophageal ulcers, history of hematemesis, uncontrolled gastro-esophageal reflux disease, inability to stay erect for 30 minutes after oral drug, history of osteonecrosis of the jaw, dental extraction or root canal in prior 8 weeks, or anticipated during the study * Calculated GFR of less than 35 mL/min * History of smoking (cigarettes, cigars, pipes, marijuana or any other substances) within the past 1 year, or \> 10 pack-years total if ≥ 18 years of age * Systemic corticosteroid treatment for any condition within 4 weeks of enrollment at Visit 1, history of significant asthma exacerbation requiring systemic corticosteroids within 4 weeks of Visit 1 or more than five courses of systemic corticosteroids in the past year, history of a life-threatening asthma exacerbation requiring intubation, mechanical ventilation, or resulting in a hypoxic seizure within the last 2 years * History of a respiratory tract infection within 4 weeks of Visit 1 * Receiving hyposensitization therapy other than an established maintenance regimen defined as a continuous regimen for ≥ 3 months prior to enrollment